Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

China flag China · Delayed Price · Currency is CNY
25.75
+0.23 (0.90%)
At close: Mar 9, 2026
28.62%
Market Cap 10.46B
Revenue (ttm) 1.62B
Net Income (ttm) 424.54M
Shares Out 406.18M
EPS (ttm) 1.06
PE Ratio 24.22
Forward PE 22.99
Dividend 0.29 (1.14%)
Ex-Dividend Date Jun 20, 2025
Volume 4,423,300
Average Volume 3,455,773
Open 25.28
Previous Close 25.52
Day's Range 25.05 - 25.87
52-Week Range 18.70 - 35.58
Beta 0.01
RSI 41.12
Earnings Date Apr 17, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 1,784
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 605116
Full Company Profile

Financial Performance

In 2024, Aurisco Pharmaceutical's revenue was 1.48 billion, an increase of 16.89% compared to the previous year's 1.26 billion. Earnings were 354.79 million, an increase of 22.59%.

Financial Statements

News

There is no news available yet.